"FDA disagreed with changes to the primary endpoint proposed...
"FDA disagreed with changes to the primary endpoint proposed by SUMMIT and subsequently incorporated in its ongoing phase 3 Ri-Codify study, "SUMMIT said in a statement.
Summit's stock tumbled 20 percent on the news, falling to $5.20 in after-hours trading. Despite the FDA's objections, Summit is moving forward with the joint study with a view to providing data in the first quarter of next year. Gao Expects the top-line results to "provide all parties with the best information on appropriate next steps for ridinilazole". $Summit Therapeutics(SMMT.US$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
